BioNTech SE Chief Executive Officer Ugur Sahin filed a Form 4 with the SEC on September 11, 2026, reporting the sale of 20,500 ordinary shares on September 10, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: Ugur Sahin disposed of 20,500 ordinary shares of BioNTech SE at a price of $96.3067 per share.
  • Transaction date: The sale occurred on September 10, 2026.
  • Direct ownership after sale: Sahin directly holds 688,209 ordinary shares following the transaction.
  • Indirect ownership: An additional 39,218,111 ordinary shares are held indirectly through Medine GmbH, of which Sahin is the sole shareholder.
  • Trading plan: The sales were effected pursuant to a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
  • Trust arrangement: 106,721 of the indirectly held shares are held for the benefit of an individual under a trust arrangement, over which Medine GmbH exercises voting power but not dispositive power.

Sahin's Share Sale Details and Ownership Structure at BioNTech

According to the filing, Ugur Sahin, Chief Executive Officer and a director and 10% owner of BioNTech SE (NASDAQ:BNTX), sold 20,500 ordinary shares on September 10, 2026, at a price of $96.3067 per share. The transaction is coded "S" (sale) in the filing. Following the transaction, Sahin directly holds 688,209 ordinary shares.

The filing discloses that Sahin also indirectly holds 39,218,111 ordinary shares through Medine GmbH, a company of which he is the sole shareholder. A footnote in the filing states that 106,721 of those indirectly held shares "are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust." The filing notes that Sahin "may be deemed to beneficially own the ordinary shares held by Medine GmbH."

The filing further states that "the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026." The form was signed by Humza Bokhari as Attorney-in-Fact on September 11, 2026. No derivative securities transactions were reported.

What Was Disclosed

BioNTech SE's CEO Ugur Sahin reported a direct sale of 20,500 ordinary shares at $96.3067 on September 10, 2026, under a Rule 10b5-1 plan. His direct holding stands at 688,209 shares, with an additional 39,218,111 shares held indirectly through Medine GmbH.